Concepedia

Stanley Wang

SW

Statistics

Publications

21

Citations

2.4K

H-Index

19

Active since

2006

Affiliations

AbbVie (United States)(Current)

Stanford University

The University of Texas at San Antonio Health Science Center

Texas Liver Institute

Southern California Reproductive Center

Stanley Wang is an author at AbbVie (United States) specializing in viral hepatitis, antiviral therapy, and virology.

ORCID

Publications per year

2006–2023

21

Publications

21

Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

Stefan Zeuzem, Graham R. Foster, Stanley Wang et al. · New England Journal of Medicine · 2018 · 437 citations · Full text

, , +17

Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis

Paul Y. Kwo, Fred Poordad, Armen Asatryan et al. · Journal of Hepatology · 2017 · 297 citations · Full text

, , +16

Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects

Elena Bekerman, Grégory Neveu, Ana Shulla et al. · Journal of Clinical Investigation · 2017 · 237 citations · Full text

, , +17

Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis

Tarik Asselah, Kris V. Kowdley, Neddie Zadeikis et al. · Clinical Gastroenterology and Hepatology · 2017 · 230 citations · Full text

, , +17

High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis

Massimo Puoti, Graham R. Foster, Stanley Wang et al. · Journal of Hepatology · 2018 · 159 citations · Full text

, , +17

1–5 of 21